International Stem Cell appoints Dr. Russell Kern as principal financial officer; granted 1M options, salary $130K

International Stem Cell CORP

Dr. Russell Kern appointed principal financial officer effective April 25, 2022.
He continues as EVP and Chief Scientific Officer.
Granted options to purchase 1,000,000 shares of common stock.
Salary increased to $130,000 per year.
Biographical information incorporated from 2022 Proxy Statement.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Russell Kern

principal financial officer

ISCO · International Stem Cell CORP

Effective: 2022-04-25
Filed: April 29, 2022, 7:59 PM ET

On April 25, 2022, International Stem Cell Corporation, a Delaware corporation (the “Company”) appointed Dr. Russell Kern as its principal financial officer effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Russell Kern was appointed as principal financial officer at International Stem Cell CORP.

Action: appointed
Role: principal financial officer

Exact text from the filing

On April 25, 2022, International Stem Cell Corporation, a Delaware corporation (the “Company”) appointed Dr. Russell Kern as its principal financial officer effective immediately.

View on SEC.gov

International Stem Cell CORP filing history →

Source: SEC EDGAR

accession 0001683168-22-003021

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.